Wearne Digital Pte Ltd v. Pfizer Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Wearne Digital Pte Ltd (Singapore)
  • Defendant: Pfizer Inc. (Delaware)
  • Plaintiff’s Counsel: Villegas & Cefo, LLP
• Case Identification: 1:26-cv-08691, S.D.N.Y., 10/02/2026
• Venue Allegations: Venue is based on Defendant maintaining a regular and established place of business in the district, including its global headquarters and a primary research facility, and having committed alleged acts of infringement related to vaccine distribution within the district.
• Core Dispute: Plaintiff alleges that Defendant’s cold chain and ultra-cold chain systems for distributing vaccines and other pharmaceuticals infringe a patent related to an integrated platform for managing the manufacture, monitoring, and deployment of therapeutic procedural packs.
• Technical Context: The technology concerns smart logistics systems for temperature-sensitive pharmaceuticals, integrating physical packaging with electronic monitoring and a data feedback loop to a central control system, a domain that gained significant market importance during the global COVID-19 vaccine rollout.
• Key Procedural History: The asserted patent claims priority from a 2018 Australian application and is a continuation of a U.S. application that entered the national stage in 2020 from a PCT filing. The complaint does not mention prior litigation or licensing involving the patent-in-suit.

Case Timeline

Date	Event
2018-02-15	'067 Patent Priority Date (Australian Application)
2019-01-30	PCT Application Filed
2020-08-12	'067 Patent's Parent Application Enters U.S. National Stage
2020-12-09	News Report on Initial Pfizer COVID Vaccine Shipment to New York City
2021-03-11	Application for '067 Patent Filed (as continuation)
2022-08-29	Plaintiff Wearne Digital Pte Ltd Registered to do Business
2022-09-27	'067 Patent Issued
2026-10-02	Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 11,456,067 - "PLATFORM AND SYSTEM FOR USE IN THERAPEUTIC PROCEDURES"

The Invention Explained

• Problem Addressed: The patent background describes the risks and inefficiencies of administering medications in non-clinical settings, citing a lack of control and information regarding the procedure (e.g., correct item usage, dosage) and the logistical challenges of responding to large-scale public health crises or biosecurity threats where medication packs may need to be rapidly manufactured and modified ("’067 Patent, col. 1:44 - col. 2:54").
• The Patented Solution: The invention proposes a system that links physical therapeutic "packs" to a central computer system ("’067 Patent, abstract"). Each pack contains a therapeutic item and an electronic communication device (e.g., RFID) ("’067 Patent, col. 3:1-8"). This device transmits data about the pack and its environment to the computer system, which processes the information and can initiate a "control response," such as modifying a step in the manufacturing process for subsequent packs ("’067 Patent, col. 3:9-24"). This creates a data-driven feedback loop from the field back to manufacturing and logistics, as illustrated in the patent's system diagram ("’067 Patent, Fig. 9").
• Technical Importance: The invention describes an integrated approach to pharmaceutical logistics, aiming to create a responsive, intelligent supply chain that can be centrally managed and adapted in real-time ("’067 Patent, col. 2:55-63").

Key Claims at a Glance

• The complaint asserts at least independent method claim 9 ("Compl. ¶67").
• The essential elements of Claim 9 include:
  • Providing a plurality of "therapeutic procedural packs," each containing a therapeutically effective item and an electronic communications device.
  • Transferring information about the pack's environment between the device and a computer system in real-time.
  • Initiating an automated control response based on the processed information.
  • Wherein the processed information enables control over the manufacture and deployment of packs.
  • And wherein the computer system's control response involves modifying a step in a therapeutic procedural pack manufacturing process so the packs include "determined therapeutically effective items."
• The complaint does not explicitly reserve the right to assert dependent claims, but this is typical practice.

III. The Accused Instrumentality

Product Identification

• The "Accused Method" is Defendant's system for distributing temperature-sensitive products, including vaccines (e.g., COMIRNATY), antibody-drug conjugates, and other pharmaceuticals requiring a cold or ultra-cold chain ("Compl. ¶¶59-61"). The "Accused Instrumentalities" are the components of this system: (i) cold chain shipping containers, (ii) GPS-enabled data loggers and temperature monitoring devices, and (iii) a connected computer system for monitoring and control ("Compl. ¶59").

Functionality and Market Context

• The complaint alleges that Defendant's system involves placing therapeutic products into thermal shipping containers along with a "GPS-enabled data logger" (e.g., from Controlant or Sensitech) that measures temperature and location ("Compl. ¶¶51, 64"). This data is transmitted wirelessly in real-time to a central monitoring platform, referred to as a "control tower" or "digital cockpit," which provides end-to-end visibility of the supply chain ("Compl. ¶¶51, 65"). This system allegedly enables Defendant to respond to events like temperature deviations by stopping a shipment in transit and dispatching a replacement from a manufacturing site ("Compl. ¶52"). The complaint further alleges that the system is a "closed-loop" process, as Defendant requires the return of the data loggers and, in some cases, the reusable shipping containers ("Compl. ¶53"). The system is described as integral to the distribution of the COMIRNATY COVID-19 vaccine ("Compl. ¶¶48, 61"). The complaint includes a diagram from a WHO presentation showing the packaging hierarchy for the Pfizer vaccine, from vial to carton to freezer case to thermal shipper ("Compl. ¶51, Fig. 3").

IV. Analysis of Infringement Allegations

'067 Patent Infringement Allegations

Claim Element (from Independent Claim 9)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
providing a plurality of therapeutic procedural packs, each therapeutic procedural pack comprising a therapeutically effective item required to conduct the therapeutic procedure and an electronic communications device having a unique identification code...	Defendant provides thermal shipping containers (the "packs") that hold a therapeutic item (e.g., a vaccine) and include a GPS-enabled data logger with a unique ID (the "electronic communications device") ("Compl. ¶¶59, 63, 68").	¶68	col. 7:15-18
transferring information about the environment surrounding and including each therapeutic procedural pack between the electronic communications device...and a computer system including a processor which processes said information in real time...	The data loggers in the shipping containers continuously measure temperature and location and transmit this data in real-time to Defendant's central "control tower" computer systems for processing ("Compl. ¶¶51, 64, 65, 68").	¶68	col. 10:3-10
initiating an automated control response...wherein said processed information enables control over manufacture...and deployment...and wherein said computer system is configured to initiate said automated control response by modifying a step in a therapeutic procedural pack manufacturing process...	The complaint alleges Defendant's "control tower" uses the real-time data to control deployment and manufacturing, citing the system's integration with manufacturing plants. It points to responses like stopping a problem shipment and dispatching a replacement as the "automated control response" that modifies the "manufacturing process" ("Compl. ¶¶52, 65, 68").	¶68	col. 12:47-53

• Identified Points of Contention:
  • Scope Questions: A central question may be whether Defendant's accused system—a combination of commercial shipping containers, third-party data loggers, and vials of medicine—constitutes a "therapeutic procedural pack" as contemplated by the patent. The patent's specification and figures describe a more specific, integrated, custom-molded kit for administering an injection ("’067 Patent, Figs. 1-8"), raising the question of whether the claim term is limited to such embodiments. Figure 9 from the Pfizer Thermal Shipping Container Catalogue illustrates the accused combination of a container, dry ice pods, vial cartons, and an embedded monitoring device ("Compl. ¶24, Fig. 9").
  • Technical Questions: The infringement allegation hinges on whether the accused "control response"—such as stopping a non-compliant shipment and dispatching a replacement from a distribution center ("Compl. ¶52")—can be said to be "modifying a step in a therapeutic procedural pack manufacturing process" as required by claim 9. The court will need to determine if "manufacturing process" can be construed to include such logistical and distribution activities, or if it is limited to the physical assembly and component selection of the packs themselves, as described in the patent specification ("’067 Patent, col. 5:4-14").

V. Key Claim Terms for Construction

• The Term: "modifying a step in a therapeutic procedural pack manufacturing process"

• Context and Importance: This term is critical because infringement of claim 9 depends on whether Defendant's alleged logistical responses (e.g., dispatching a replacement shipment) meet this definition. The Plaintiff's theory appears to equate this logistical action with a modification of a manufacturing process.

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The claim links control over "manufacture" with "deployment," suggesting a broad, end-to-end process ("’067 Patent, claim 9"). The patent also discusses using the system for "supply and inventory management purposes" ("’067 Patent, col. 6:18-19"), which could support reading logistical actions into the claim scope.
  • Evidence for a Narrower Interpretation: The specification provides specific examples of modifying a manufacturing process, such as a computer system controlling "a 3D printing facility or injection moulding plant to produce packs" customized to a threat ("’067 Patent, col. 5:9-14"; "’067 Patent, col. 13:62 - col. 14:4"). This language may support an interpretation limited to altering the physical fabrication or composition of the pack itself, not just its distribution.

• The Term: "therapeutic procedural pack"

• Context and Importance: The infringement case rests on the idea that Defendant's shipping containers, filled with vials and a data logger, are "therapeutic procedural packs." Practitioners may focus on this term because the patent's own figures depict a very different physical object.

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The patent uses the terms "platform" and "pack" interchangeably ("’067 Patent, col. 3:5-8"), and the abstract describes a "portable therapeutic platform," suggesting a functional rather than strictly structural definition. The claims do not specify the physical form of the pack.
  • Evidence for a Narrower Interpretation: The detailed description and Figures 1-8 show a specific, custom-molded container with dedicated compartments for a syringe, disposal device, and ampoules ("’067 Patent, col. 7:35 - col. 8:5"). This consistent, detailed depiction of a specific physical embodiment could be used to argue that the term "pack" should be construed more narrowly than simply any container holding a therapeutic item.

VI. Other Allegations

• Indirect Infringement: The complaint alleges only direct infringement under Count I ("Compl. ¶¶67-68") and does not plead a separate count for indirect or induced infringement.
• Willful Infringement: The complaint does not use the word "willful" but does seek enhanced damages under 35 U.S.C. § 284 and a declaration of an exceptional case for attorneys' fees under § 285 ("Compl. ¶¶69, 70g"). The basis for such an award may be post-suit conduct, as the complaint alleges Defendant "has infringed and continues to directly infringe" the '067 Patent, which issued in September 2022, four years before the complaint was filed ("Compl. ¶¶34, 67").

VII. Analyst’s Conclusion: Key Questions for the Case

• A core issue will be one of definitional scope: can the term "therapeutic procedural pack," which is exemplified in the patent as an integrated injection kit, be construed to cover Defendant's system of physically separate shipping containers, data loggers, and vials of medicine?
• A second key issue will be the interpretation of action: does "modifying a step in a... manufacturing process," as claimed in the patent, encompass the logistical action of dispatching a replacement shipment from inventory, or is it strictly limited to altering the physical fabrication or assembly of the pack itself? The outcome of the case may turn on whether a supply chain management response qualifies as a manufacturing modification.